Leal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedLoading investors…
Activity from announced rounds
Develops neuro-metabolic therapeutics for schizophrenia and ALS
AI-first clinical enablement company and developer of remote physical examination technology featuring FDA-cleared medical devices
Pitching OrbiMed? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room